CV Therapeutics, Inc. (Nasdaq: CVTX) announced that ranolazine significantly (p
Recent Posts
- Trexima(TM) (Sumatriptan/Naproxen Sodium) Provided Relief Of Both Traditional And Non-traditional Migraine Symptoms
- FDA Accepts Guided Therapeutics' Non-Invasive Cervical Cancer Scanner PMA Application For Review
- Peregrine Pharmaceuticals Reports Progress In Cotara(R) Brain Cancer Clinical Program
- Biodel Reports New Findings From Key Programs At Diabetes Technology Meeting
- Hair Straightening Chemicals Not Linked To Breast Cancer Risk In African-Americans
- Sopherion Therapeutics, LLC Announces Publication Of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data In Advanced Breast Cancer Patients
- Head And Neck Cancer Survivors Who Use Alcohol And Cigarettes Have Increased Death Risk
- Shedding Light On Cancer Cells
- Elan And Biogen Idec Initiate First Clinical Trial Of TYSABRI(R) In Oncology - First Multiple Myeloma Patient Treated
- Portrait(R) Plasma Skin Regeneration
- Increase In Thyroid Cancer Not Explained By Screening Alone